Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Federation Francophone de Cancerologie Digestive |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00416858 |
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain.
PURPOSE: This randomized phase III trial is studying radiation therapy together with combination chemotherapy to see how well they work with or without surgery in treating patients with locally advanced esophageal cancer that can be removed by surgery.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer |
Drug: cisplatin Drug: fluorouracil Procedure: adjuvant therapy Procedure: conventional surgery Procedure: neoadjuvant therapy Radiation: radiation therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Official Title: | Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer |
Estimated Enrollment: | 40 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to gender, histology (epidermoid vs glandular), response to induction therapy (complete vs partial), and tumor differentiation (little differentiated vs undifferentiated/good vs moderately differentiated).
After completion of study therapy, patients are followed periodically.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed epidermoid or glandular cancer of the esophagus meeting the following criteria:
PATIENT CHARACTERISTICS:
Must be able to maintain sufficient enteral nutrition (2,000 calories/day)
PRIOR CONCURRENT THERAPY:
Study ID Numbers: | CDR0000453783, FFCD-9102, EU-20539, ESSAI-FFCD-9102 |
Study First Received: | December 27, 2006 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00416858 History of Changes |
Health Authority: | United States: Federal Government |
stage III esophageal cancer |
Antimetabolites Digestive System Neoplasms Immunologic Factors Gastrointestinal Diseases Esophageal Neoplasms Adjuvants, Immunologic Esophageal Cancer Immunosuppressive Agents |
Digestive System Diseases Cisplatin Esophageal Disorder Head and Neck Neoplasms Fluorouracil Gastrointestinal Neoplasms Esophageal Diseases |
Antimetabolites Digestive System Neoplasms Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Gastrointestinal Diseases Esophageal Neoplasms Physiological Effects of Drugs Immunosuppressive Agents |
Pharmacologic Actions Neoplasms Digestive System Diseases Neoplasms by Site Therapeutic Uses Head and Neck Neoplasms Fluorouracil Gastrointestinal Neoplasms Esophageal Diseases |